NCT02248805 - Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

July 2, 2018

Study Completion Date

July 2, 2018

Conditions

Colorectal Carcinoma

Interventions

DRUG

MGD007

MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.

Trial Locations (8)

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

Duke University Medical Center, Durham

Carolina Biooncology Institute, Huntersville

H. Lee Moffitt Cancer Center & Research Institute, Inc, Tampa

Providence Portland Medical Center, Portland

Yale University, Yale Cancer Center, New Haven

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston